The Short Version
CDC and WHO data confirm BA.3.2 was detected in at least 23 countries and demonstrates enhanced antibody escape in laboratory testing — both factual pillars of the claim hold up. However, describing the immune escape as "significant" without qualification overstates the real-world picture: WHO rates BA.3.2 as low additional public health risk, vaccines are still expected to protect against severe disease, and the variant shows reduced infectivity with no consistent growth advantage. The core facts are accurate, but the framing omits important context.